Haemonetics Corporation — Form 8-K Summary
Event date: October 8, 2026. This Form 8-K reports an update concerning the company’s non-exclusive supply agreement with CSL Plasma; it does not report quarterly financial results.
Business context and agreement update
CSL announced that it expects to complete the rollout of Haemonetics’ NexSys PCS devices with Persona PLUS technology and related disposables by the end of calendar 2027. CSL has informed Haemonetics that it currently anticipates transitioning all of its current U.S. plasma collection centers. The agreement was disclosed in an August 18, 2026 Form 8-K.
Financial metrics and comparison
The filing provides no revenue, profit, cash flow, margin, debt, liquidity, or other financial results, and no comparable-period figures. It does not quantify the agreement’s expected financial impact.
Guidance, outlook, and risks
- Haemonetics is not changing its previously issued fiscal 2027 guidance at this time.
- The company expects to update its anticipated fiscal 2027 financial impact in connection with its second-quarter earnings call in November 2026.
- Rollout scope and timing may change under the agreement, and implementation details remain to be determined by CSL and Haemonetics.
- Risks include customer adoption and demand, CSL purchase timing and volumes, changes to CSL’s transition plans, and Haemonetics’ ability to manufacture and supply products on schedule.
Key facts for investors to verify
- Whether CSL proceeds with the anticipated rollout across all current U.S. centers and completes it by the end of 2027.
- Actual purchase volumes and the timing of orders under the non-exclusive agreement.
- Haemonetics’ November 2026 update on the agreement’s expected fiscal 2027 financial impact and any change to guidance.
- Whether Haemonetics can meet CSL’s manufacturing and supply requirements.
The Item 7.01 information is furnished, not filed for purposes of Section 18 of the Exchange Act.